SCHEMBL9923263

SCHEMBL9923263

CNc1ccc2c(=O)c(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(C)s4)cc3F)cc(=O)[nH]c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.44
KIT P10721 4/20 0.42
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
AR P10275 1/20 0.37
MAOA P21397 1/20 0.35
CA12 O43570 5/20 0.35
CA9 Q16790 5/20 0.35
KDR P35968 4/20 0.35
LCK P06239 3/20 0.33
CSF1R P07333 3/20 0.33
LYN P07948 3/20 0.33
SRC P12931 3/20 0.33
FLT1 P17948 3/20 0.33
FLT4 P35916 3/20 0.33
FLT3 P36888 3/20 0.33
BLK P51451 3/20 0.33
CA1 P00915 2/20 0.33
FYN P06241 2/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12161718 0.92 P2RY12 (0.54) P2RY12KITKMT2AMEN1AR
SCHEMBL12177512 0.90 P2RY12 (0.42) P2RY12KITKMT2AMEN1AR
SCHEMBL9922399 0.88 P2RY12 (0.43) P2RY12KITKMT2AARMAOA
SCHEMBL12177674 0.86 P2RY12 (0.40) P2RY12KITKMT2AMEN1AR
SCHEMBL14113588 0.84 P2RY12 (0.49) P2RY12KITKMT2AMEN1AR
SCHEMBL12177435 0.84 CA12 (0.41) P2RY12KITKMT2AMEN1CA12
SCHEMBL9923254 0.83 P2RY12 (0.49) P2RY12KITKMT2AMEN1AR
SCHEMBL9922563 0.81 P2RY12 (0.49) P2RY12KMT2AMEN1MAOASTING1
SCHEMBL12161696 0.79 P2RY12 (0.53) P2RY12KITKMT2AMEN1AR
SCHEMBL12177432 0.79 P2RY12 (0.58) P2RY12KITKMT2AMEN1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885KIT 399/4885KMT2A 3009/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885KIT 398/4885KMT2A 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.